企業プロフィール
4D Molecular Therapeutics, Inc. 株価・ニュース・カタリスト
- ティッカー:
- FDMT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
13.84 USD (-3.28%)
終値
最終更新: 2026年10月1日
485M USD
時価総額
株価変動の要因
最新のモニタリング対象企業ニュースは「4DMT to Host Investor Day on October 21, 2026」です。対応する終値の反応はまだ確認できません。
企業概要
Genetic Medicines Company
4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids.
4D-150 Retinal Franchise
4D-150 is an intravitreal dual-transgene therapy that expresses both aflibercept and an anti-VEGF-C molecule. It is being developed for wet age-related macular degeneration and diabetic macular edema with the goal of providing durable control after a single administration.
Late-Stage Ophthalmology Development
The 4FRONT pivotal program evaluates 4D-150 in wet age-related macular degeneration, while a separate Phase 3 strategy is advancing in diabetic macular edema. These studies position ophthalmology as the company's principal near-term value driver.
Broader Retinal Pipeline
4D-175 is being developed for geographic atrophy and extends the platform beyond VEGF-driven retinal disease. The program reflects the company's ability to design vectors and payloads for additional degenerative eye conditions.
Aerosol Gene Therapy for Cystic Fibrosis
4D-710 is an inhaled gene therapy intended to deliver a functional CFTR transgene to airway cells. The program targets people with cystic fibrosis who may not benefit adequately from existing CFTR modulators.
今後のカタリスト
- Initiation of a Phase 3 study of 4D-150 in diabetic macular edema in the third quarter of 2026.
- Two-year SPECTRA data for 4D-150 in diabetic macular edema in the fourth quarter of 2026.
- Updated AEROW clinical data for 4D-710 in cystic fibrosis in the fourth quarter of 2026.
- Topline results from the 4FRONT-1 pivotal study of 4D-150 in the second quarter of 2027.
- Topline results from the 4FRONT-2 pivotal study of 4D-150 in the second half of 2027.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。